Market view
Stock chart
Coverage
Analyses on CAN Fite BIO (4)
- May 4, 2026
- March 26, 2026March 26, 2026
- Follow-up
Which Trial Can Actually Move Can-Fite in 2026-2027?
The first event on the calendar is pancreatic cancer in Q3 2026, but the trial most likely to change how Can-Fite is judged is LIVERATION in HCC. Psoriasis matters, yet its proof burden is less clean, and MASH still lacks a dated milestone.
- Follow-up
Can-Fite After March 2026: Funding Layer, Dilution and the Warrant Stack
March 2026 bought Can-Fite operating time, but it did so by swapping immediate liquidity pressure for a warrant stack that is now almost the size of the current equity base.
Can-Fite in 2025: The Clinical Calendar Is Filling Up, but Financing Still Runs the Story
Can-Fite enters 2026 with a denser clinical calendar, but shareholder value still depends on funding its way to data without reopening the dilution loop.
Same sector
